Rheumatoid arthritis

Biosimilar Ixifi Gets FDA Approval for All Remicade Indications

By December 14, 2017

Ixifi is a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor.

RAS Inhibitor Use May Cut Risk of MI in Rheumatoid Arthritis Patients

By December 08, 2017

The use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) was associated with a reduced risk of myocardial infarction (MI) among patients with rheumatoid arthritis (RA).

Anti-Inflammatory Foods May Help With RA Symptoms, Progression

By November 08, 2017

Specific foods that were highlighted include dried plums, blueberries, pomegranates, whole grains, ginger, turmeric, specific oils, and teas; these foods were found to reduce inflammatory cytokines, joint stiffness, pain, and oxidative stress.

Simponi Aria Approved for Psoriatic Arthritis, Ankylosing Spondylitis

By October 23, 2017

The FDA's expanded approvals were supported by data from two Phase 3 multicenter, randomized, double-blind, placebo-controlled studies (GO-VIBRANT and GO-ALIVE) that included >600 patients.

Biosimilar Cyltezo Gets FDA Approval for Multiple Indications

By August 28, 2017

This marks the second approval of a biosimilar for adalimumab.

FDA Committee Votes Against RA Drug Candidate Approval

By August 03, 2017

Sirukumab, a human monoclonal IgG1 kappa antibody, works differently than current IL-6 inhibitors approved to treat RA by targeting the IL-6 cytokine vs. the IL-6 receptor.

Cost-Effectiveness of First-Line RA Strategies Compared

May 31, 2017

First-line etanercept-methotrexate would result in 0.15 additional lifetime QALY, at cost of 77,290

Tofacitinib Goes Head-to-Head with Adalimumab in RA Study

By February 16, 2017

Tofacitinib plus MTX was shown to be non-inferiority vs. adalimumab plus MTX, however, Xeljanz monotherapy did not meet its primary endpoint for non-inferiority vs.adalimumab plus MTX, or vs. Xeljanz plus MTX.

Odds of Epilepsy May Go Up in Kids Exposed to Maternal RA

November 17, 2016

Some children born to mothers with rheumatoid arthritis (RA) may have higher-than-average odds of developing epilepsy, according to a study published online in Neurology.

Smoking Leads to Worse RA Flare and Remission Patterns

By November 16, 2016

Tobacco smoking adversely impacts rheumatoid arthritis (RA) flare and remission rates, according to findings from a long-term retrospective, population-based cohort study, presented at the 2016 ACR/ARHP Annual Meeting.

Temporary MTX Discontinuation Ups Flu Vaccine Efficacy in RA

By November 16, 2016

Temporarily discontinuing methotrexate (MTX) treatment can improve seasonal influenza vaccination immunogenicity among patients with rheumatoid arthritis (RA), according to a single center, randomized, single-blind, open-label prospective study (NCT02748785) presented at the 2016 ACR/ARHP Annual Meeting.

Infliximab vs. Biosimilar: Discontinuation Rates Compared

By November 16, 2016

Medical records of 1,044 patients with RA, new to starting treatment with Remicade or CT-P13, were analyzed in the study.

Anti-TNF Agents Go Head-to-Head in RA Superiority Study

By November 16, 2016

The trial compares short- and long-term outcomes of Cimzia and Humira in RA

Large RA Survey Finds 61% of Patients Uncomfortable Voicing Concerns

By November 16, 2016

Results from a global survey given to patients and physicians showed that good communication is "critical to achieve optimal care".

Sarilumab Offers Durable Clinical Responses for RA After 3 Years

By November 16, 2016

The IL-6Rα -targeting human mAb sarilumab offers durable responses against rheumatoid arthritis (RA), according to an analysis of 3-year clinical and radiographic outcomes and safety for patients from the MOBILITY open-label extension study.

Sarilumab Efficacy, Safety Comparable Among RA Patient Subgroups

By November 16, 2016

The IL-6Rα -targeting human mAb sarilumab exhibits comparable efficacy and safety for different patient subgroups in rheumatoid arthritis.

Biosimilars for Rheumatic Diseases: Safety, Efficacy of Switching Assessed

By November 15, 2016

The investigators found switching data for 12 studies in rheumatic diseases.

How Do DMARDs Alter Diabetes Risk in Rheumatoid Arthritis?

November 15, 2016

Hydroxychloroquine use was associated with a duration-dependent reduction in risk of developing diabetes.

Adding Adalimumab to Methotrexate in RA Halts Radiographic Progression

By November 13, 2016

In patients with early RA, conventional synthetic DMARDs are recommended as first-line therapy

For RA Patients, DMARDs May Protect Against Bone Loss

By November 08, 2016

A new review has found disease-modifying anti-rheumatic drugs (DMARDs) to be effective in halting progressive bone loss in rheumatoid arthritis (RA) patients, and suggests that they should be used early in treatment.

Oral Baricitinib Evaluated in RA Unresponsive to Conventional DMARDs

By June 09, 2016

Eli Lilly and Incyte announced positive data from the pivotal study, RA-BEYOND, evaluating baricitinib vs. placebo for the treatment of rheumatoid arthritis (RA). Study findings were presented at the Annual European Congress of Rheumatology (EULAR 2016) in London.

Tocilizumab Shows Superiority in RA Patients After Non-TNFi Failure

March 30, 2016

For patients with rheumatoid arthritis (RA) and a first non-tumor necrosis factor inhibitor (TNFi) failure, treatment with tocilizumab seems more efficacious than abatacept or rituximab

Herpes Zoster Risk in RA Up With Older Age, Prednisone Dose

December 11, 2015

Patients with rheumatoid arthritis (RA) have increased herpes zoster (HZ) risk with older age and higher prednisone dose, according to a study published in Arthritis Care & Research.

Lower RA Activity for Patients Seen at Practices With NPs, PAs

December 10, 2015

Patients with rheumatoid arthritis (RA) have lower disease activity when seen at practices with nurse practitioners (NPs) or physician assistants (PAs) versus rheumatologist-only practices, according to a study published in Arthritis Care & Research.